129 related articles for article (PubMed ID: 32997342)
21. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
[TBL] [Abstract][Full Text] [Related]
23. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
24. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type
Chandler T; Furmanek S; Carrico R; Balcom D; Arnold F; Ramirez J
Microorganisms; 2022 Mar; 10(3):. PubMed ID: 35336135
[TBL] [Abstract][Full Text] [Related]
25. Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan.
Yamana H; Ono S; Michihata N; Uemura K; Jo T; Yasunaga H
Clin Microbiol Infect; 2023 Jul; 29(7):904-910. PubMed ID: 37044276
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
28. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
29. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center.
Masuda T; Nakatani E; Shirai T; Akamatsu T; Tamura K; Takahashi S; Tanaka Y; Watanabe H; Endo Y; Suzuki T; Saigusa M; Yamamoto A; Morita S; Sato Y; Asada K
BMC Pulm Med; 2021 Apr; 21(1):123. PubMed ID: 33863300
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
33. Dual influenza and pneumococcal vaccination was associated with lower short-term risks of all-cause and acute respiratory hospitalizations among the elderly in Shenzhen, China: a retrospective cohort study.
Jiang Y; Ye Z; Chen D; Shu Y
Emerg Microbes Infect; 2020 Dec; 9(1):2578-2587. PubMed ID: 33215981
[TBL] [Abstract][Full Text] [Related]
34. Interrupted time-series analyses of routine vaccination program for elderly pneumonia patients in Japan; an ecological study using aggregated nationwide inpatient data.
Kobayashi K; Jo T; Mimura W; Suzukawa M; Ohshima N; Tanaka G; Akazawa M; Matsui H; Fushimi K; Yasunaga H; Nagase T; Nagai H
Hum Vaccin Immunother; 2021 Aug; 17(8):2661-2669. PubMed ID: 33877954
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with pneumococcal vaccine uptake in elderly subjects referred to the respiratory department.
Watanabe K; Asai Y; Tsurikisawa N; Oshikata C; Kaneko T
Nagoya J Med Sci; 2020 Aug; 82(3):469-476. PubMed ID: 33132431
[No Abstract] [Full Text] [Related]
39. Prior pneumococcal vaccination improves in-hospital mortality among elderly population hospitalized due to community-acquired pneumonia.
Kim S; Kim MJ; Myong JP; Lee YH; Kim BY; Hwang A; Kim GO; Jeong SH; Yoon HK; An TJ; Lim JU
BMC Pulm Med; 2024 Apr; 24(1):168. PubMed ID: 38589839
[TBL] [Abstract][Full Text] [Related]
40. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
